SearchCatalogResearchTools
Research & Educational Use Only. This protocol guide is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before beginning any research protocol.
Weight Loss StackEvidence Grade: A (Semaglutide) / B (AOD-9604)

Semaglutide + AOD-9604 Stack Protocol Guide

⚠ No validated human dose. This compound is not FDA-approved and has no peer-reviewed human dose-finding trials. The figures below are research conventions extrapolated from preclinical (animal/in‑vitro) and community sources — not validated clinical dosing. Treat them as study references only. Research use only; not medical advice.

The Semaglutide + AOD-9604 stack combines the most powerful GLP-1 receptor agonist with a targeted fat-loss peptide for enhanced body composition results. Semaglutide suppresses appetite via central GLP-1 signaling, slows gastric emptying, and improves insulin sensitivity, while AOD-9604 (a modified fragment of human growth hormone amino acids 177-191) directly stimulates lipolysis without growth-promoting or diabetogenic effects. Together, these compounds address fat loss through complementary mechanisms: reduced caloric intake via appetite suppression and direct fat mobilization from adipose tissue.

Protocol Overview

Compounds
Semaglutide + AOD-9604
Category
Weight Loss / Fat Loss Stack
Mechanism
Semaglutide: GLP-1 receptor agonism, appetite suppression, gastric slowing. AOD-9604: lipolysis stimulation via beta-3 adrenergic pathway, lipogenesis inhibition
Half-Life
Semaglutide: ~7 days | AOD-9604: ~4-6 hrs
Route
Semaglutide: SubQ (weekly) | AOD-9604: SubQ (daily)
Frequency
Semaglutide: 1x/week | AOD-9604: 1x daily (AM fasted)
Cycle Length
12-16 weeks

Synergy & Mechanism

Semaglutide Mechanism

Semaglutide activates GLP-1 receptors in the hypothalamus and gut, producing powerful appetite suppression, delayed gastric emptying, and improved insulin sensitivity. In clinical trials (STEP program), semaglutide produced 15-20% body weight reduction. It addresses the behavioral component of fat loss by dramatically reducing hunger and cravings.

AOD-9604 Synergy

AOD-9604 is the lipolytic fragment of HGH (amino acids 177-191) that directly stimulates fat breakdown in adipose tissue without affecting blood sugar or growth. While semaglutide reduces caloric intake from the top down, AOD-9604 attacks stored fat from the bottom up, specifically mobilizing stubborn adipose deposits that resist diet alone.

Combined Dosing Protocol

ProtocolCompound 1Compound 2TimingDuration
StandardSema 0.25mg/wk (wk1-4), 0.5mg (wk5-8), 1mg (wk9+)AOD 300mcg/dayAM fasted12-16 weeks
AggressiveSema titrate to 2.4mg/wkAOD 500mcg/dayAM fasted16 weeks
MaintenanceSema 0.5mg/wkAOD 300mcg EODAM fasted8 weeks

Reconstitution & Preparation

Semaglutide Preparation

  • Pre-filled pens or compounded lyophilized vials
  • If compounded: reconstitute per pharmacy label
  • Store refrigerated 2-8°C
  • Weekly injection, same day each week

AOD-9604 Preparation

  • AOD-9604 vial: typically 5mg lyophilized
  • Reconstitute with 2mL BAC water = 2,500mcg/mL
  • 300mcg dose = 12 units on insulin syringe
  • Refrigerate, use within 30 days

Stacking Schedule (AM/PM Timing)

AM Protocol (Fasted)

  • 6:00-7:00 AM: AOD-9604 300mcg subcutaneous, abdomen
  • Wait 30-60 min before eating
  • Semaglutide: once weekly (any time, same day)
  • Fasted cardio amplifies AOD fat mobilization

PM Protocol

  • No PM injections required
  • Maintain caloric deficit for best results
  • Stay hydrated; semaglutide can cause dehydration
  • Protein intake: 1g per lb lean body mass minimum

Expected Timeline

Week 1-2
Semaglutide titration at 0.25mg. Appetite suppression emerges gradually. AOD-9604 begins lipolytic action. Possible mild nausea.
Week 3-4
Noticeable hunger reduction. AOD-9604 fat mobilization compounds. Early scale changes of 2-4 lbs typical.
Week 5-8
Semaglutide at 0.5mg. Significant appetite control. Visible body composition changes. 5-10 lbs loss common.
Week 9-16
Full-dose semaglutide (1-2.4mg) with AOD. Accelerated fat loss from stubborn areas. 15-25 lbs total loss achievable.

Side Effects & Monitoring

Common Side Effects

  • Nausea, especially during semaglutide titration (most common)
  • Constipation or diarrhea
  • Injection site reactions (mild)
  • Headache during first weeks
  • Reduced appetite (therapeutic effect)

Precautions

  • MTC family history - semaglutide contraindication
  • Pancreatitis history
  • Gallbladder disease risk with rapid weight loss
  • Monitor for hypoglycemia if on diabetes meds
  • Not for use during pregnancy

Blood Work Recommendations

PanelMarkersTiming
MetabolicFasting glucose, HbA1c, fasting insulinBaseline, Week 8, Week 16
LipidTotal cholesterol, LDL, HDL, triglyceridesBaseline, Week 8, Week 16
ThyroidTSH, free T4Baseline, Week 8
Liver/KidneyCMP, ALT, AST, lipaseBaseline, Week 8

Monitor metabolic markers closely. Semaglutide typically improves HbA1c and lipid profiles. Watch lipase for pancreatitis risk.

Related Protocols & Tools

Dosing CalculatorReconstitution CalcBloodwork PlannerStack Checker
★ OFFICIAL SPONSOR
BioRoot AI
Free Functional Assessment
AI-powered root cause analysis & care plan
Start Free
Preferred vendor ยท Learn more
Share & Save
๐• Share on Twitter ๐Ÿ“ฑ Share on Reddit ๐Ÿ’ฌ WhatsApp โœ‰๏ธ Email ๐Ÿ”— Copy Link ๐Ÿ–จ๏ธ Print / Save PDF โ˜… Save to Favorites
⚠ Before any use: human safety data is limited or absent for many of these compounds. Consult a licensed healthcare provider first — especially if you are pregnant or nursing, have a medical condition, or take other medications.